Cargando…

Curative treatment can be an option for patients with metastatic squamous cell cancer of the head and neck

BACKGROUND: No specific study has focused on patients with metastatic squamous cell carcinoma of the head and neck (SCCHN) at diagnosis. Due to high response rates of induction chemotherapy in chemo-naïve patients with localized disease, their prognosis should be better than patients with recurrent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guenne, Clémence, Fayette, Jérôme, Cosmidis, Alain, Fuchsmann, Carine, Tartas, Sophie, Favrel, Véronique, Céruse, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271786/ https://www.ncbi.nlm.nih.gov/pubmed/25548517 http://dx.doi.org/10.2147/DDDT.S70451

Ejemplares similares

An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents
por: Péron, Julien, et al.
Publicado: (2014)

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma
por: Fayette, Jérôme, et al.
Publicado: (2015)

Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma
por: Karabajakian, Andy, et al.
Publicado: (2020)

Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03
por: Fayette, Jerome, et al.
Publicado: (2017)

Addendum: Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma
por: Karabajakian, Andy, et al.
Publicado: (2022)

Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients
por: Fayette, Jérôme, et al.
Publicado: (2016)

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Argiris, Athanassios, et al.
Publicado: (2017)

Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
por: Chevalier, Thomas, et al.
Publicado: (2021)

Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Question of Belief
por: Karabajakian, Andy, et al.
Publicado: (2018)

Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule
por: Pêtre, Adeline, et al.
Publicado: (2018)

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borel, Christian, et al.
Publicado: (2020)

Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation
por: Wildsmith, Sophie, et al.
Publicado: (2022)

Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age
por: Saba, Nabil F., et al.
Publicado: (2019)

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck(†)
por: Seiwert, T. Y., et al.
Publicado: (2014)

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wildsmith, Sophie, et al.
Publicado: (2023)

190. Osteomyelitis Following Mandibular Reconstruction with Free Fibula Flap: A Cohort Study of an Emerging and Complex Bone and Joint Infection
por: javaux, Clément, et al.
Publicado: (2020)

Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review
por: Winquist, Eric, et al.
Publicado: (2017)

Dihydroisotanshinone I as a Treatment Option for Head and Neck Squamous Cell Carcinomas
por: Hsu, Cheng-Ming, et al.
Publicado: (2021)

Osteopontin Levels in Patients with Squamous Metastatic Head and Neck Cancer
por: Maleš, Josip, et al.
Publicado: (2021)

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial(†)
por: Clement, P. M., et al.
Publicado: (2016)

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
por: Ho, Alan L., et al.
Publicado: (2021)

Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR
por: Gilbert, Jill, et al.
Publicado: (2015)

Dosimetric comparison of VMAT standard optimization (SO) and multi‐criteria optimization (MCO) treatment plans with standard mode delivery (STD) or sliding window (SW) for head and neck cancer
por: Rolland, Julien, et al.
Publicado: (2023)

Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers
por: Ortiz-Cuaran, Sandra, et al.
Publicado: (2021)

Predicting 90-Day Mortality in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma after Curative Surgery
por: Qin, Lei, et al.
Publicado: (2018)

Localized Drug Delivery Systems: An Update on Treatment Options for Head and Neck Squamous Cell Carcinomas
por: Hariharan, Arvind, et al.
Publicado: (2023)

The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality
por: Ferrari, Daris, et al.
Publicado: (2020)

Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands
por: van der Linden, Naomi, et al.
Publicado: (2015)

Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
por: Chen, Wen-Chun, et al.
Publicado: (2017)

Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
por: Baa, Annie Kanchan, et al.
Publicado: (2023)

Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study
por: Vienne, Agathe, et al.
Publicado: (2023)

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck
por: Pivot, X, et al.
Publicado: (2001)

Mechanisms of cyst formation in metastatic lymph nodes of head and neck squamous cell carcinoma
por: Mokhtari, Sepideh
Publicado: (2012)

Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer
por: Lorch, Jochen H
Publicado: (2009)

Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck
por: Sukari, Ammar, et al.
Publicado: (2015)

Socioeconomic factors and survival in patients with non‐metastatic head and neck squamous cell carcinoma
por: Xu, Cheng, et al.
Publicado: (2017)

Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma
por: Arron, Sarah T., et al.
Publicado: (2022)

Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy
por: Chen, Yen-Hao, et al.
Publicado: (2017)

Surviving Elderly Patients with Head-and-Neck Squamous Cell Carcinoma—What Is the Long-Term Quality of Life after Curative Radiotherapy?
por: Rühle, Alexander, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6b0b69bhik1l2l0nck9ql70mtv